

1 **Rapid carbapenem inactivation method (rCIM): A new**
2 **phenotypic method for rapidly detecting**
3 **carbapenemase-producing *Enterobacteriales***

4 **Yameng Liu¹, Liang Luan², Jing Liu² and Nan Wan^{2*}**

5 **Abstract**

6 **Background:** Rapid and accurate methods for detecting carbapenemase-producing
7 *Enterobacteriales* (CPE) are essential for improving patient prognosis and preventing
8 the spread of these microbes. In this study, 103 carbapenem-resistant
9 *Enterobacteriales* (CRE) isolates were collected from clinical specimens; of these, 55
10 CRE isolates were included in the retrospective analysis, and 48 CRE isolates were
11 included in the prospective evaluation. Using sequencing results as the gold standard,
12 we evaluated the performance of the rapid carbapenem inactivation method (rCIM)
13 for detecting carbapenemases in comparison with the modified carbapenem
14 inactivation method (mCIM) and CNPt-Direct test. In rCIM, the test isolate was
15 incubated with meropenem (MEM) disks, and the supernatant obtained via
16 centrifugation was incubated with the indicator strain *Escherichia coli* ATCC 25922.
17 Growth of the indicator strain was monitored using a nephelometer.

18 ***Correspondence:** wannan@outlook.com

19 ¹Post Graduate Training Base of General Hospital of Northern Theater Command, Jinzhou
20 Medical University, Jinzhou, Liaoning Province, China

21 ²Department of Clinical Laboratory, General Hospital of Northern Theater Command, Shenyang,
22 Liaoning Province, China

23 **Results:** The cut-off value of rCIM was 0.50 McFarland units. In retrospective
24 analysis, the percent positive agreement and percent negative agreement of rCIM for
25 detecting carbapenemase were 97.1% and 100%, respectively, and these values were
26 higher than those for mCIM and the CNPt-Direct test. In the prospective evaluation,
27 rCIM was linked to a sensitivity and specificity of 96.4% and 95%, respectively.
28 **Conclusion:** rCIM may be a rapid (<3 h), economical, simple, and reliable method
29 for screening CPE isolates, and it is expected to be routinely implemented in clinical
30 microbiology laboratories.

31 **Keywords:** rCIM, carbapenem-resistant *Enterobacteriales*, carbapenemase, mCIM,
32 CNPt-Direct test

33 **Background**

34 *Enterobacteriales* comprises a large group of gram-negative bacilli with similar
35 biological characteristics, and these microbes are common causes of hospital-acquired
36 and community-acquired infections [1]. Carbapenems are the last line of defense
37 against *Enterobacteriales* infections. The worldwide emergence and spread of
38 carbapenem-resistant *Enterobacteriales* (CRE) represent a public health threat [2-3].
39 The carbapenem resistance mechanisms include the production of carbapenemase,
40 high efflux pumps expression, and production of extended-spectrum β-lactamase
41 (ESBL) and/or AmpC β-lactamase in combination with mutations that decrease the
42 permeability of the bacterial cell to the entry of carbapenems, but carbapenemase
43 production is the main mechanism [4-5]. Studies have revealed that
44 carbapenemase-producing *Enterobacteriales* (CPE) has higher toxicity, easier

45 transmission, poorer prognosis, and higher mortality than
46 non-carbapenemase-producing *Enterobacteriales* (NPE) [6]. Therefore, the early and
47 accurate detection of CPE is extremely important for infection control and for
48 epidemiologic and therapeutic purposes.

49 Although molecular methods remain the gold standard [7-8], they are complex and
50 costly, their use is limited by the targets used in the test, and they are not accessible to
51 all microbiology laboratories worldwide. Therefore, phenotype-based assays are
52 urgently needed for carbapenemase screening in clinical microbiology laboratories. At
53 present, several phenotypic methods are available for detecting carbapenemase,
54 including MALDI-TOF carbapenem hydrolysis assays [7], biochemical methods
55 (Carba NP) [7], immunological tests (RESIST-3 O.K.N., NG-Test CARBA 5) [9-10],
56 growth-based assays (modified Hodge test), and the modified carbapenem
57 inactivation method (mCIM) [7]. The growth-based assays require at least 18–24 h,
58 which delays detection. The MALDI-TOF carbapenem hydrolysis assays,
59 immunological methods, and Carba NP test require only 15 min to 4 h to obtain
60 results. Because of the high cost of mass spectrometers, MALDI-TOF assays cannot
61 be widely implemented in all microbiology laboratories. The immunological methods
62 only target the 3–5 most common carbapenemases. The Carba NP test interprets the
63 result visually based on color changes, and the result is greatly affected by the
64 personnel who judge the results, which can easily lead to false-negative or
65 false-positive results.

66 Carbapenem inactivation method (CIM)-based tests have attracted widespread

67 interest in clinical microbiology since 2015, and many studies have described the
68 simplicity, low cost, and high sensitivity and specificity of CIM assays for the
69 detection of CPE [11-14]. CIM assesses the growth of the indicator strain *Escherichia*
70 *coli* ATCC 25922 around meropenem disk that were previously incubated with the
71 test isolate. If meropenem in the disk is hydrolyzed by carbapenemase expressed by
72 the test organism, *E. coli* ATCC 25922 will grow to the edge of the disk or exhibit a
73 diminished zone of growth inhibition. Conversely, a zone of growth inhibition
74 indicates that MEM in the disk is active and that the test isolate does not produce a
75 carbapenemase. mCIM was developed by Dr. Sanchita Das and colleagues
76 (unpublished work) both to overcome the limited sensitivity of CIM for certain
77 enzyme classes and increase the simplicity of the method (purchasing 2 mL of TSB
78 broths versus aliquoting 400 µL of water). In 2017, the Clinical and Laboratory
79 Standards Institute (CLSI) recommended mCIM as the phenotype test for detecting
80 carbapenemase [15-16]. In 2018, CLSI also added mCIM and
81 ethylenediaminetetraacetic acid (EDTA)-CIM into as standard microbial susceptibility
82 tests for screening carbapenemases and differentiating serine enzymes [17].

83 In this study, we introduced the rapid carbapenem inactivation method (rCIM), a
84 new variant of CIM, and judged whether the test isolate produced carbapenemase by
85 measuring the McFarland index of the indicator strain ATCC 25922. The method
86 shortens the detection time to 2–2.5 h. In this study, we compared rCIM with
87 sequencing and other phenotype tests (mCIM and CNPt-Direct) to evaluate its
88 performance and provided evidence for clinical treatment and the prevention of

89 nosocomial infections.

90 **Results**

91 **Establishment of the rCIM positive cut-off value**

92 In the positive control, the MEM disks were inactivated, indicating that the growth of
93 the indicator strain ATCC 25922 was unhindered. The median (min–max)
94 baseline-subtracted values at 1.5 and 2 h were 0.84 (0.79–0.92) and 1.33 (1.31–1.37)
95 McFarland units, respectively. In the negative control, the growth of ATCC 25922 was
96 inhibited by MEM disks, and the median values (min–max) at 1.5 and 2 h were 0.15
97 (0.13–0.18) and -0.02 (-0.04–0.01) McFarland units, respectively. There was no
98 obvious growth difference between the positive and negative controls before 1.5 h,
99 whereas a significant difference was identified after 1.5 h. According to the
100 calculation rule of cut-off value, we established 0.50 McFarland units as the rCIM
101 positive cut-off value, which was 3-fold higher than the median negative control at
102 1.5 h, and evaluated the value using a retrospective and prospective collection of 103
103 CRE isolates.

104 **Retrospective analysis**

105 In the retrospective analysis, the 55 organisms and their sequencing and phenotypic
106 methods results are presented in Table 3. The growth of the indicator strain is
107 presented in Figure 1, and the results indicated an apparent growth difference between
108 the CPE and NPE isolates. At 1.5 h, rCIM accurately detected 31/35 CPE isolates, and
109 the median (min–max) was 1.92 (0.22–2.50) McFarland units. In addition, the value
110 did not reach 0.5 McFarland units (0.44, 0.38, and 0.49, respectively) for three *E.*

111 *cloacae* isolates at 1.5 h , but the values all exceeded 0.50 McFarland units (1.10, 0.78,
112 and 0.88, respectively) at 2 h. At 2 h, the majority of isolates (34/35) had reached 0.50
113 McFarland units with the median (min–max) reaching 2.47 (0.46–3.06). One blaNDM
114 *E. cloacae* isolate grew to 0.46 McFarland units at 2 h. rCIM detected 20/20 NPEs,
115 and the median values (min–max) at 1.5 and 2 h were 0.03 (-0.10–0.17) and 0.05
116 (-0.12–0.15) McFarland units, respectively. In the retrospective analysis, the percent
117 positive and negative agreement of rCIM for detecting CPE were 97.1% and 100%,
118 respectively, and κ was 0.961.

119 In the retrospective analysis, mCIM accurately detected 32/35 CPEs and 20/20
120 NPEs, whereas false-negative results were obtained for three isolates (blaKPC *K.*
121 *pneumoniae*, blaNDM *E. coli*, and blaNDM *E. cloacae*). The percent positive
122 agreement, percent negative agreement, and κ of mCIM were 91.4%, 100%, and
123 0.886, respectively. CNPt-Direct accurately detected 33/35 CPEs and 20/20 NPEs,
124 including two false-negative results (blaKPC *K. pneumoniae* and blaIMP *K. oxytoca*),
125 and the percent positive agreement, percent negative agreement, and κ were 94.3%,
126 100%, and 0.923.

127 **Prospective evaluation**

128 The sequencing, rCIM, mCIM, and CNPt-Direct results for 48 organisms are
129 presented in Table 4. The growth of the indicator strain *E. coli* ATCC 25922 is shown
130 in Figure 2. In total, 27/28 CPE isolates were detected by rCIM, and the median
131 values (min–max) at 1.5 and 2 h were 1.32 (-0.07–1.71) and 1.97 (-0.05–2.39)
132 McFarland units, respectively. A false-negative result was obtained for isolate of

133 blaNDM *P. mirabilis*, reaching -0.05 McFarland units at 2 h. rCIM detected 19/20
134 NPEs, with the median values (min–max) at 1.5 and 2 h reaching 0.03 (-0.15–0.55)
135 and 0.06 (-0.12–2.16) McFarland units, respectively. A false-positive result was
136 recorded for one PCR-negative *K. pneumoniae* isolate, and the values at 1.5 and 2 h
137 were 0.55 and 2.16 McFarland units, respectively. In the prospective evaluation, the
138 sensitivity, specificity, positive predictive value, negative predictive value, and κ of
139 rCIM were 96.4%, 95%, 96.4%, 95%, and 0.914, respectively.

140 In the prospective evaluation, mCIM accurately detected 18/28 CPE and 19/20
141 NPE isolates, and false-negative results were obtained for 10 isolates (three *K.*
142 *pneumoniae*, two *E. coli*, three *E. cloacae*, one *P. mirabilis*, and one *E. aerogenes*
143 isolate). One PCR-negative *K. pneumoniae* isolate had an inhibition zone diameter of
144 6 mm, which denoted a false-positive result. The sensitivity, specificity, positive
145 predictive value, negative predictive value, and κ of mCIM were 64.3%, 95%, 94.7%,
146 65.5%, and 0.557, respectively. CNPt-Direct accurately detected 23/28 CPE and
147 19/20 NPE isolates, whereas false-negative and false-positive results were recorded
148 for five isolates (two *K. pneumoniae*, one *E. coli*, one *P. mirabilis*, and one *E.*
149 *aerogenes* isolate) and one isolate (PCR-negative *K. pneumoniae*), respectively.
150 CNPt-Direct had a sensitivity, specificity, positive predictive value, negative
151 predictive value, and κ of 82.1%, 95%, 95.8%, 79.2%, and 0.750, respectively. The
152 sensitivity and consistency of rCIM were better than those of the other phenotypic
153 tests (mCIM and CNPt-Direct), but there was no difference among the groups
154 concerning specificity.

155 **Discussion**

156 Carbapenemase-encoding genes are mostly located in mobile genetic elements such as
157 bacterial plasmids, integrants, and transposons, and they can easily spread among
158 bacteria when the outer membrane is damaged and/or permeability increases, thereby
159 explaining the widespread spread of carbapenem-resistant Enterobacteriaceae isolates
160 globally [18-19]. Therefore, a method for rapidly and effectively detecting
161 carbapenemase is urgently required. In this study, we evaluated a new phenotypic
162 method for the rapid detection of carbapenemases. rCIM correctly detected 61/63
163 CPE and 39/40 NPE isolates, giving an overall sensitivity of 96.8% and specificity of
164 97.5%, which were slightly lower than the values reported by Muntean *et al.* [20].
165 These lower results may be related to the insufficient sample size. In general, rCIM is
166 an excellent method for the rapid screening of CPE.

167 In this study, the CRE isolates were mainly *K. pneumoniae* (52.4%), followed by *E.*
168 *coli* (23.3%) and *E. cloacae* (15.5%). The carbapenem resistance mechanisms of *K.*
169 *pneumoniae* in our hospital were mainly the production of *Klebsiella pneumoniae*
170 carbapenemase (KPC, 48.1%), which is consistent with relevant domestic reports [21].
171 There were two false-negative results and one false-positive result for rCIM in this
172 study. In the retrospective analysis, one isolate of blaNDM *E. cloacae* had a growth
173 value of 0.46 McFarland units at 2 h, approaching the positive cut-off value of 0.50,
174 which may be related to the weaker activity of the carbapenemase. Another isolate of
175 blaNDM *P. mirabilis* reached a value of -0.05 McFarland units at 2 h, and the
176 CNPt-Direct result was also negative, which may be related to the non-expression or

177 low expression of carbapenemase. In addition, a false-positive result was obtained for
178 one PCR-negative *K. pneumoniae* isolate, with the growth of the indicator strain
179 reaching 2.16 McFarland units at 2 h, and the CNPt-Direct result was also positive,
180 probably linked to the limited number of primers used in our study.

181 In this study, only blaKPC, blaNDM, and blaIMP were detected, and blaVIM- and
182 blaOXA-positive isolates were not found, which was in accordance with the
183 epidemiology of carbapenemase in China [7,22-23]. In the retrospective analysis,
184 three *E. cloacae* isolates exhibited increased growth to 0.44, 0.38, and 0.49
185 McFarland units at 1.5 h, respectively, but the growth of the indicator strain further
186 increased to 1.10, 0.78, and 0.88 McFarland units at 2 h, respectively, indicating the
187 importance of the additional 30 min of incubation. Another isolate of blaNDM *E.*
188 *cloacae* had an increase in growth to 0.46 McFarland units at 2 h, approaching the
189 cut-off value of 0.50 McFarland units. To reduce the occurrence of false-negative and
190 false-positive results, the test isolate with growth near the positive cut-off value of
191 0.50 McFarland units at 2 h needs to be re-tested or further tested using other tests
192 (molecular or immunological methods). In addition, the per-test cost of rCIM is
193 extremely low, requiring only 2.5 mL of TSB broth and two MEM disks, comparable
194 to the requirements for other phenotypic experiments. All isolates used in our study
195 were obtained from blood plates, and the performance of rCIM when applied to other
196 culture media requires further research.

197 rCIM, a variant of CIM, is a test for the rapid and accurate detection of
198 carbapenemase. CIM and its variants have higher sensitivity than Carba NP when

199 detecting low-activity carbapenemases [20,24-25]. As reported by Caméléná *et al.*
200 (2018), the CIMPlus test used EDTA as an inhibitor for detecting MBL and
201 phenylboronic acid (PBA) as a class A enzyme inhibitor, and this test can detect
202 carbapenemases at 8 and 20 h and identify the type of carbapenemase at 20 h.
203 CIMplus had sensitivities of 95.7 and 97.8% at 8 and 20 h, respectively, and a
204 specificity of 94.4%, and the characterization was correct for 100, 96.9, and 100% of
205 class A, B, and D enzymes, respectively [26]. According to Bianco *et al.* (2019), the
206 direct β -lactamase inactivation method rapidly detects β -lactamase and
207 carbapenemase from positive blood culture bottles within several hours, and it had a
208 sensitivity of 99% and specificity of 100% when detecting KPC, NDM, and
209 oxacillinase-48 enzymes [27].

210 The performance of rCIM should be further evaluated using more types of
211 carbapenemase and more diverse bacteria species, such as *Acinetobacter* and
212 *Pseudomonas*. Clavulanic acid and tazobactam can effectively inhibit class A
213 carbapenemases, aztreonam has activity against MBL, and cephalosporins and
214 aztreonam can treat infections caused by class D carbapenemase-expressing microbes.
215 Therefore, we can attempt to add EDTA and PBA to identify the type of
216 carbapenemase in the first incubation of rCIM. We can also attempt to directly detect
217 the production of carbapenemase from positive blood culture bottles and provide
218 timely feedback the results to the clinician.

219 **Conclusion**

220 Our research revealed that rCIM is a rapid (2–2.5 h), inexpensive, and reliable

221 phenotype test that can quantitatively detect all carbapenemases, and its sensitivity
222 and consistency were higher than those of mCIM and CNPt-Direct, making it
223 routinely useful for small microbiology laboratories.

224 **Methods**

225 **Retrospective isolates**

226 Two separate cohorts were included, including a retrospective cohort of 55
227 carbapenem-resistant *Enterobacteriales* isolates and a prospective cohort of 48 clinical
228 isolates. The retrospective isolates were obtained from our hospital between January
229 2016 and September 2018 and previously were molecularly characterized (PCR and
230 gene sequencing) to identify carbapenemase genes. The retrospective collection
231 included 35 CPE isolates carrying the following carbapenemase genes: *blaKlebsiella*
232 *pneumoniae* carbapenemase (KPC), nine isolates; *bla*New Delhi metallo- β -lactamase
233 (NDM), 23 isolates; *bla*imipenemase (IMP), two isolates; *bla*KPC plus NDM, one
234 isolate; and NPE, 20 isolates. The 55 CRE isolates consisted of *E. coli* (n = 16),
235 *Enterobacter cloacae* (n = 11), *Klebsiella pneumoniae* (n = 22), and *Klebsiella*
236 *oxytoca* (n = 6).

237 **Prospective isolates**

238 From October 2018 to May 2019, 48 clinical CRE isolates were collected in our
239 hospital for prospective research, including 28 CPE and 20 NPE isolates. The CPE
240 isolates carried the following carbapenemase genotypes: *bla*KPC, 17 isolates;
241 *bla*NDM, eight isolates; *bla*KPC plus NDM, one isolate; and *bla*NDM plus IMP, two
242 isolates. This collection of CRE isolates included the following organisms: *K.*

243 *pneumoniae* (n = 32), *E. cloacae* (n = 5), *E. coli* (n = 8), *E. aerogenes* (n = 1), *E.*
244 *asburiae* (n = 1), and *Proteus mirabilis* (n = 1). All isolates were stored at -80°C, and
245 after thawing, the isolates were subcultured on a blood agar plate before testing. Each
246 isolate was identified via MALDI-TOF mass spectrometry (Bruker Daltonik GmbH,
247 Bremen, Germany). Carbapenem (imipenem, MEM, and ertapenem) susceptibility
248 testing was performed using the Vitek 2 Compact gram-negative panel (bioMérieux,
249 Marcy l'Étoile, France) and K-B disk diffusion method and interpreted according to
250 the 2018 CLSI guidelines.

251 **rCIM**

252 rCIM was derived from mCIM [16]. Briefly, two 10- μ g MEM disks (Oxoid Ltd.,
253 Hampshire, United Kingdom) were added to 1 mL of distilled water containing two
254 10- μ L loopfuls of an overnight isolate, incubated for 30 min at 35 ± 2°C, and
255 centrifuged at 10,000 rpm for 5 min (high-mucus isolate with a positive mucus
256 filament test needs to be centrifuged twice). The prepared 2.5 mL of tryptic soy broth
257 (TSB) (Oxoid Ltd.) were taken from a 4°C refrigerator and left at room temperature
258 for 30 min, after which a 1.0 McFarland unit suspension of *E. coli* ATCC 25922 was
259 created. Then, 500 μ L of the centrifugal supernatant were added, and the mixture was
260 incubated at 35 ± 2°C for 2 h. The growth of the indicator strain *E. coli* was assessed
261 using a nephelometer (bioMérieux) every 30 min, and the McFarland unit results were
262 recorded after subtracting the baseline. For every experiment, the positive and
263 negative controls were *K. pneumoniae* ATCC BAA-1705 and ATCC BAA-1706,
264 respectively.

265 **Other phenotypic methods**

266 mCIM was performed following the 2018 CLSI guideline [16-17]. A 1- μ L loopful of
267 the CRE isolate was suspended in 2 mL of TSB containing a 10- μ g MEM disk and
268 incubated for 4 \pm 0.25 h at 35 \pm 2°C. Subsequently, the MEM disk was removed from
269 the TSB broth at the end of the 4-h incubation using a 10- μ L inoculation loop and
270 placed on a Mueller–Hinton agar plate freshly plated with a 0.50 McFarland unit
271 suspension of *E. coli* ATCC 25922. Then, the plate was incubated at 35 \pm 2°C for
272 18–24 h. The mCIM result was interpreted according to the inhibition zone, as shown
273 in Table 1.

274 The CNPt-Direct test was derived from the Carba NP test [28]. Solution A of the
275 CNPt-Direct contains 100 μ L of 0.05% phenol red solution consisting of 0.1 mmol/L
276 ZnSO₄•7H₂O and 0.1% (vol/vol) Triton X-100 (Solarbio, Beijing, China), and the pH
277 of solution was adjusted to 7.8 \pm 0.1. Solution B contains 100 μ L of solution A
278 supplemented with 12 mg/mL intravenous (i.v.) imipenem-cilastatin sodium (Merck
279 Pharmaceutical Co., Ltd., Hangzhou, China) immediately before use. Solutions A and
280 B were added to a 96-well microtiter plate (Biotech Engineering Co., Ltd., Shanghai,
281 China), and a 1- μ L loopful of the test isolate was directly suspended in each well. The
282 96-well microtiter plate was vortexed for 5–10 s and then incubated at 35 \pm 2°C for 2
283 h. All isolates were tested in triplicate, and the test was repeated in the case of
284 discrepant results. A color change from red to orange/yellow in the solution B reaction
285 well was interpreted as a positive result. Two independent technicians interpreted the
286 results. In each test, *K. pneumoniae* ATCC BAA-1705 and ATCC BAA-1706 were

287 used as the positive and negative controls, respectively.

288 **PCR detection of carbapenemase genes**

289 In all retrospective and prospective isolates, DNA was extracted using a bacterial
290 DNA extraction kit (Biotech Engineering Co.), and primers were designed to detect
291 the carbapenemase genes (*blaKPC*, *blaNDM*, *blaIMP*, *blaOXA-48-like*, and
292 *blaVIM*), as shown in Table 2. Carbapenemase gene amplification was examined
293 using a PCR kit (Biotech Engineering Co.) with PCR amplification equipment
294 (Hongshi Medical Technology Co., Ltd., Shanghai, China). Briefly, amplification was
295 performed using a protocol consisting of initial denaturation at 94°C for 5 min
296 followed by 36 cycles of denaturation at 94°C for 45 s, annealing at 55°C for 45 s,
297 and extension at 72°C for 1 min, and final elongation at 72°C for 10 min. The PCR
298 products were electrophoresed on a 2% agarose gel at a voltage of 100 for 1 h using
299 an electrophoresis set (Junyi Dongfang Electrophoresis Equipment Co., Ltd., Beijing,
300 China), and the results were read on a gel imager (Junyi Dongfang Electrophoresis
301 Equipment Co., Ltd.). PCR products were selected and sent to an outside company
302 (Biotech Engineering Co., Ltd.) for sequencing, and sequences were aligned using the
303 BLAST software tool.

304 **Statistical analysis**

305 The sensitivity, specificity, and positive and negative predictive values of rCIM and
306 other phenotypic tests were calculated using SPSS 22.0 software, and these results
307 were analyzed using the kappa value (κ) in comparison with the sequencing results.
308 $\kappa > 0.75$ indicated that the two methods are in good agreement, $\kappa = 0.4-0.75$ indicated

309 moderate agreement, and $\kappa < 0.4$ indicated poor agreement.

310 **Abbreviations**

311 PCR: Polymerase Chain Reaction; CLSI: Clinical and Laboratory Standards Institute; CPE:
312 carbapenemase-producing *Enterobacteriales*; CRE: carbapenem-resistant *Enterobacteriales*; mCIM: modified
313 carbapenem inactivation method; rCIM: rapid carbapenem inactivation method; ESBL: extended-spectrum
314 β -lactamase; NPE: non-carbapenemase-producing *Enterobacteriales*

315 **Acknowledgements**

316 We thank Joe Barber Jr., PhD, from Liwen Bianji, Edanz Editing China (www.liwenbianji.cn/ac), for editing the
317 English text of a draft of this manuscript.

318 **Authors' contributions**

319 Conceived and designed the study: NW and YL. Conducted the experiments and analyzed the results: NW, YL, LL,
320 and JL. Drafted the manuscript: YL and NW. All authors contributed to manuscript revision, read and approved the
321 submitted version.

322 **Funding**

323 This project was internally funded. External funding bodies had no role in the study design, data collection,
324 analysis, interpretation or writing of the manuscript.

325 **Availability of data and materials**

326 The datasets used and/or analysed during the current study are available from the corresponding author on
327 reasonable request.

328 **Ethics approval and consent to participate**

329 Not applicable.

330 **Consent for publication**

331 Not applicable.

332 **Competing interests**

333 The authors declare that they have no competing interests.

334 **References**

335 1. Duin D, Paterson DL. Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned. *Infect*

336 *Dis Clin NorthAm.* 2016;30:377–390.

337 2. Livermore DM. Current epidemiology and growing resistance of gram-negative pathogens. *Korean J Intern*

338 *Med.* 2012;27:128–142.

339 3. Sun K, Xu X, Yan J, Zhang L. Evaluation of Six Phenotypic Methods for the Detection of Carbapenemases

340 in Gram-Negative Bacteria With Characterized Resistance Mechanisms. *Ann Lab Med.* 2017;37:305–312.

341 4. Goodman KE, Simner PJ, Tamma PD, Milstone AM. Infection control implications of heterogeneous

342 resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE). *Expert Rev Anti Infect Ther.*

343 2016;14:95–108.

344 5. Lutgring JD, Limbago BM. The Problem of

345 Carbapenemase-Producing-Carbapenem-Resistant-Enterobacteriaceae Detection. *J Clin Microbiol.*

346 2016;54:529–534.

347 6. Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, et al. Comparing the Outcomes of

348 Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant

349 Enterobacteriaceae Bacteremia. *Clin Infect Dis.* 2017;64:257–264.

350 7. Zhou M, Wang D, Kudinha T, Yang Q, Yu S, Xu YC. Comparative Evaluation of Four Phenotypic Methods

351 for Detection of Class A and B Carbapenemase-Producing Enterobacteriaceae in China. *J Clin Microbiol.*

352 2018;56:e00395-18.

- 353 8. Doret L, Fusaro M, Naas T. Improvement of the Xpert Carba-R Kit for the Detection of
- 354 Carbapenemase-Producing Enterobacteriaceae. *Antimicrob Agents Chemother.* 2016;60:3832–3837.
- 355 9. Glupczynski Y, Jousset A, Evrard S, Bonnin RA, Huang TD, Doret L, et al. Prospective evaluation of the
- 356 OKN K-SeT assay, a new multiplex immunochemical test for the rapid detection of OXA-48-like,
- 357 KPC and NDM carbapenemases. *J Antimicrob Chemother.* 2017;72:1955–1960.
- 358 10. Boutal H, Vogel A, Bernabeu S, Devilliers K, Creton E, Cotellon G, et al. A multiplex lateral flow
- 359 immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like
- 360 carbapenemase-producing Enterobacteriaceae. *J Antimicrob Chemother.* 2018;73: 909–915.
- 361 11. Zwaluw K, Haan A, Pluister GN, Bootsma HJ, Neeling AJ, Schouls LM. The carbapenem inactivation
- 362 method (CIM), a simple and low-cost alternative for the Carba NP test to assess phenotypic carbapenemase
- 363 activity in gram-negative rods. *PLoS One* 2015;10:e0123690.
- 364 12. Gauthier L, Bonnin RA, Doret L, Naas T. Retrospective and prospective evaluation of the Carbapenem
- 365 inactivation method for the detection of carbapenemase-producing Enterobacteriaceae. *PLoS One*
- 366 2017;12:e0170769.
- 367 13. Aguirre-Quiñonero A, Cano ME, Gamal D, Calvo J, Martínez-Martínez L. Evaluation of the carbapenem
- 368 inactivation method (CIM) for detecting carbapenemase activity in enterobacteria. *Diagn Microbiol Infect*
- 369 *Dis.* 2017;88:214–218.
- 370 14. Akhi MT, Khalili Y, Ghotaslou R, Kafil HS, Yousefi S, Nagili B, et al. Carbapenem inactivation: a very
- 371 affordable and highly specific method for phenotypic detection of carbapenemase-producing *Pseudomonas*
- 372 *aeruginosa* isolates compared with other methods. *J Chemother.* 2017;29:144–149.
- 373 15. CLSI. Performance standards for antimicrobial susceptibility testing. 27th ed. Wayne, PA: Clinical and
- 374 Laboratory Standards Institute; 2017.

- 375 16. Laolerd W, Akeda Y, Preeyanon L, Ratthawongjirakul P, Santanirand P. Carbapenemase-Producing
- 376 Carbapenem-Resistant Enterobacteriaceae from Bangkok, Thailand, and Their Detection by the Carba NP
- 377 and Modified Carbapenem Inactivation Method Tests. *Microb Drug Resist.* 2018;24:1006–1011.
- 378 17. CLSI. Performance standards for antimicrobial susceptibility testing. 28th ed. Wayne, PA: Clinical and
- 379 Laboratory Standards Institute; 2018.
- 380 18. Carattoli A. Plasmids and the spread of resistance. *Int J Med Microbiol.* 2013;303:298–304.
- 381 19. Antunes NT, Lamoureux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. Class D β -lactamases: are they
- 382 all carbapenemases?. *Antimicrob Agents Chemother.* 2014;58: 2119–2125.
- 383 20. Muntean MM, Muntean AA, Gauthier L, Creton E, Cotellon G, Popa MI, et al.. Evaluation of the rapid
- 384 carbapenem inactivation method (rCIM): a phenotypic screening test for carbapenemase-producing
- 385 Enterobacteriaceae. *J Antimicrob Chemother.* 2018;73:900–908.
- 386 21. Li H, Zhang J, Liu Y, Zheng R, Chen H, Wang X, et al.. Molecular characteristics of
- 387 carbapenemase-producing Enterobacteriaceae in China from 2008 to 2011: predominance of KPC-2 enzyme.
- 388 *Diagn Microbiol Infect Dis.* 2014;78:63–65.
- 389 22. Zhang R, Liu L, Zhou H, Chan WE, Li J, Fang Y, et al.. Nationwide Surveillance of Clinical
- 390 Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. *EBioMedicine.* 2017;19:98–106.
- 391 23. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu B, et al.. Epidemiology of Carbapenem-Resistant
- 392 Enterobacteriaceae Infections: Report from the China CRE Network. *Antimicrob Agents Chemother.*
- 393 2018;62:e01882-17.
- 394 24. Madkour LA, Soliman MS, Hassan DM, Soliman NS, ElMahdy YA. Detection of carbapenemase-producers:
- 395 evaluating the performance of the carbapenem inactivation method and Carba NP test versus multiplex PCR.
- 396 *J Glob Antimicrob Resist.* 2017; 9:10–14.

- 397 25. Baeza LL, Pfennigwerth N, Greissl C, Göttig S, Saleh A, Stelzer Y, et al.. Comparison of five methods for
 398 detection of carbapenemases in Enterobacteriales with proposal of a new algorithm. Clin Microbiol Infect.
 399 2019;25: 1286.e9–1286.e15.
- 400 26. Caméléna F, Cointe A, Mathy V, Hobson C, Doit C, Bercot B, et al.. Within-a-Day Detection and Rapid
 401 Characterization of Carbapenemase by Use of a New Carbapenem Inactivation Method-Based Test, CIMplus.
 402 J Clin Microbiol. 2018;56:e00137-18.
- 403 27. Bianco G, Boattini M, Iannaccone M, Fossati L, Cavallo R, Costa C. Direct β -Lactam Inactivation Method: a
 404 New Low-Cost Assay for Rapid Detection of Carbapenemase- or
 405 Extended-Spectrum- β -Lactamase-Producing Enterobacteriales Directly from Positive Blood Culture
 406 Bottles. J Clin Microbiol. 2019;58:e01178-19.
- 407 28. Pasteran F, Tijet N, Melano RG, Corso A. Simplified Protocol for Carba NP Test for Enhanced Detection of
 408 Carbapenemase Producers Directly from Bacterial Cultures. J Clin Microbiol. 2015;53:3908–3911.
- 409 29. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes.
 410 Diagn Microbiol Infect Dis. 2011;70:119–123.

411 **Table 1.** Interpretation of the modified carbapenem inactivation method (mCIM)
 412 result

	Zone Size		
mCIM	6 to 15mm or 16 to 18mm with pinpoint colonies in the zone of growth	16 to 18mm or ≥ 19 mm with pinpoint colonies in the zone of growth	≥ 19 mm inhibition

Interpretation	Positive (carbapenemase producer)	Indeterminate	Negative (non-carbapenemase producer)
----------------	---	---------------	---

413 **Table 2.** Primers for the detection of carbapenemase-producing *Enterobacteriales*

Carbapenemase gene	Primer sequences ^a (5'-3')	Amplicon size (bp)	Reference
blaKPC	CGTCTAGTTCTGCTGTCTTG CTTGTCAATCCTTGTAGGCG	798 232	[29]
blaNDM	GGTTTGGCGATCTGGTTTC CGGAATGGCTCATCACGATC	621	[29]
blaIMP	GGAATAGAGTGGCTTAAYTCTC GGTTAAAYAAAACAACCAACC	232	[29]
blaOXA-48-like	GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG	438	[29]
blaVIM	ATCGCAACGCAGTCGTTGA CCCGCTCGATGAGAGTCCTT	318	Corporate synthesis

414 ^aThe first and second primers for each gene are the forward and reverse primers, respectively. KPC, *Klebsiella*
415 *pneumoniae* carbapenemase; NDM, New Delhi metallo-β-lactamase; IMP, imipenemase; OXA-48-like,
416 Oxacillinase-48-like; VIM, Verona integron-encoded metallo-β-lactamase.

417 **Table 3.** Results of rCIM, mCIM, and CNPt-Direct for 55 CRE isolates in the
418 retrospective analysis

Organism (n)	Species	No. of	rCIM	mCIM	CNPt-Direct
--------------	---------	--------	------	------	-------------

solates

carbapenemase producer (35)

				+	8/9+	8/9+
Class A (9)						
KPC (9)	<i>K. pneumoniae</i>	9		+	8/9+	8/9+
Class B (25)						
NDM (23)	<i>E. coli</i>	8		+	7/8+	+
	<i>E. cloacae</i>	10		9/10+	9/10+	+
	<i>K. pneumoniae</i>	2		+	+	+
	<i>K. oxytoca</i>	3		+	+	+
IMP (2)	<i>K. oxytoca</i>	2		+	+	1/2+
Coproducers (1)						
KPC-NDM (1)	<i>K. pneumoniae</i>	1		+	+	+
non-carbapenemase producer (20)						
	<i>E. coli</i>	8		-	-	-
	<i>E. cloacae</i>	1		-	-	-
	<i>K. pneumoniae</i>	10		-	-	-
	<i>K. oxytoca</i>	1		-	-	-

419 rCIM, rapid carbapenem inactivation method; mCIM, modified carbapenem inactivation method; CRE,
 420 carbapenem-resistant *Enterobacteriales*; KPC, *Klebsiella pneumoniae* carbapenemase; NDM, New Delhi
 421 metallo-β-lactamase; IMP, imipenemase; +, positive; -, negative.

422 **Table 4.** Results of rCIM, mCIM, and CNPt-Direct for 48 CRE isolates in the
 423 prospective evaluation

Organism (n)	Species	No. of				
		isolates	rCIM	mCIM	CNPt-Direct	
carbapenemase producer (28)						
Class A (17)						
KPC (17)	<i>K. pneumoniae</i>	16	+	14/16+	14/16+	
	<i>E. coli</i>	1	+	-	-	
Class B (8)						
NDM (8)	<i>E. coli</i>	1	+	-	+	
	<i>E. cloacae</i>	1	+	-	+	
	<i>K. pneumoniae</i>	4	+	3/4+	+	
	<i>P. mirabilis</i>	1	-	-	-	
	<i>E. aerogenes</i>	1	+	-	-	
Coproducers (3)						
KPC-NDM (1)	<i>E. cloacae</i>	1	+	+	+	
NDM-IMP (2)	<i>E. cloacae</i>	2	+	-	+	
non-carbapenemase producer (20)						
	<i>E. coli</i>	6	-	-	-	
	<i>E. cloacae</i>	1	-	-	-	
	<i>K. pneumoniae</i>	12	11/12-	11/12-	11/12-	
	<i>E. asburiae</i>	1	-	-	-	

424 rCIM, rapid carbapenem inactivation method; mCIM, modified carbapenem inactivation method; CRE,

425 carbapenem-resistant *Enterobacteriales*; KPC, *Klebsiella pneumoniae* carbapenemase; NDM, New Delhi

426 metallo- β -lactamase; IMP, imipenemase; +, positive; -, negative

427 **Fig. 1. The growth of the indicator strain *Escherichia coli* ATCC 25922 in the**
428 **retrospective analysis.** The box plot showing the growth of *E. coli* ATCC 25922 at
429 1.5 and 2 h in the retrospective analysis ($n = 55$). The hollow circles represent the
430 outliers. The horizontal black line at 0.50 McFarland units represents the positive
431 cut-off value. The results are presented as baseline-subtracted McFarland units, and
432 measurements were performed every 30 min.

433 **Fig. 2. The growth of the indicator strain *Escherichia coli* ATCC 25922 in the**
434 **prospective evaluation.** A box plot presenting the growth of *E. coli* ATCC 25922 at
435 1.5 and 2 h in the prospective evaluation ($n = 48$). The hollow circles represent the
436 outliers, and the asterisks indicate extreme values. The horizontal black line at 0.50
437 McFarland units represents the positive cut-off value. The results are presented as
438 baseline-subtracted McFarland units, and measurements were performed every 30
439 min.